Partnering
Cloud Pharmaceuticals has over 20 early stage drug programs in discovery, preclinical research and animal studies, both directly and in partnership with academic and commercial organizations. A portion of its programs include:
- A beta-CR peptide inhibitor with promising animal data, suitable for reducing chemotherapy side effects
- A pro-drug design for Crohn's Disease
- A novel drug candidate for Dengue fever
- Several cancer drug candidates for novel targets, including, but not limited to Metnase, DNA polymerase beta and PD-1
- A selective small molecule inhibitor for PDHK2 for Congenital pyruvate dehydrogenase complex (PDC) deficiency
- Several clinical stage rare disease assets discovered with AI to repurpose existing drugs
- A Phase 2 stage thrombosis drug program